Fischer-Betz R, Schneider M
Klinik für Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
Z Rheumatol. 2009 Sep;68(7):584, 586-90. doi: 10.1007/s00393-008-0412-4.
In contrast to many other medications, chloroquine and hydroxychloroquine are approved treatment options for systemic lupus erythematosus (SLE). Antimalarials reduce the frequency of disease flares and contribute to the maintenance of remission. Apart from its direct effects on SLE activity, antimalarials seem to protect against thrombotic events and have a beneficial effect on glucose and lipid profiles, which might help reduce the high cardiovascular risk of SLE. Hydroxychloroquine is the only treatment shown to be effective in reducing the risk of damage accrual in SLE patients. Finally, antimalarials are inexpensive, especially compared with more recent treatments, and are well tolerated in SLE. Despite all these benefits, still only about 40%-50% of SLE patients are treated with (hydroxy)chloroquine. Particularly in early disease phases, antimalarials should be considered for every lupus patient, assuming there are no contraindications.
与许多其他药物不同，氯喹和羟氯喹是系统性红斑狼疮（SLE）的获批治疗选择。抗疟药可降低疾病发作频率并有助于维持缓解状态。除了对SLE活动有直接影响外，抗疟药似乎还能预防血栓形成事件，并对血糖和血脂水平产生有益影响，这可能有助于降低SLE患者较高的心血管风险。羟氯喹是唯一被证明对降低SLE患者损伤累积风险有效的治疗药物。最后，抗疟药价格低廉，尤其是与近期的治疗方法相比，并且在SLE患者中耐受性良好。尽管有这些益处，但仍只有约40%-50%的SLE患者接受（羟）氯喹治疗。特别是在疾病早期阶段，假设没有禁忌证，应为每位狼疮患者考虑使用抗疟药。
